RE: Coming weeks DoseMeRx/Predict26 Jun 2026 07:32
The key phrases are:
“the Board looks forward to updating shareholders on further operational and commercial developments in the weeks ahead…”
That is stronger than saying “in due course” or “as appropriate.” Saying “in the weeks ahead” suggests management expects newsflow relatively soon.
Then they specifically single out:
“…including developments associated with Predict-Onc and DoseMe.”
That’s important because they didn’t have to name those two programmes. By doing so, they’re effectively signalling that those are where investors should be looking.
Reading between the lines, it could mean they’re expecting one or more of the following:
* A commercial agreement or partnership.
* A new customer win.
* Progress on integrating Predict-Onc into clinical workflows.
* Validation data or case studies.
* Licensing discussions.
* Revenue-generating announcements.
It’s also interesting that they say:
“A more comprehensive and in-depth review… will be provided within the forthcoming annual report.”
That tells me there is a bigger strategic story they aren’t ready to fully tell yet, probably because they’re constrained by timing or ongoing commercial discussions. Companies often avoid discussing negotiations until they’re sufficiently advanced.
My interpretation
I’d put it like this:
* Bullish interpretation (around 70%): Management is intentionally preparing shareholders for a period of regular positive updates over the next few weeks.
* Very bullish interpretation (around 30%): They already know a significant commercial announcement is close but can’t release it until agreements are signed.
I do think this paragraph is unusually forward-looking. It feels as though the board wanted to reassure investors that this update isn’t the end of the story—it is the start of a period of expected newsflow.
I’d be watching for RNS announcements over the next month or two relating to DoseMe commercial progress and Predict-Onc partnerships, because the company has specifically highlighted those rather than speaking in general terms.
Sign In
Follow the stocks
